At EASD 2025, Novo Nordisk presented results from the INFORM survey of 550 people taking Wegovy® (semaglutide) for weight management. Respondents reported a 46% drop in constant intrusive thoughts about food, alongside gains in mental health (64%), healthier habits (80%), and improved lifestyle (76%).
Dr. Robert Gabbay noted in a post on LinkedIn that weight loss is only part of the story. For many people with obesity, the harder challenge is the constant mental chatter around food. Addressing this burden could help people maintain healthier behaviors and improve quality of life.
These results come from a survey, not a randomized clinical trial, so causality cannot be established. The group surveyed was not representative of everyone taking Wegovy®: 86% were women, with an average age of 53. And while 550 participants provides meaningful insight, I wonder if a few hundred people is enough to draw broad conclusions, even if the number is reasonable for early findings.
Gabbay also emphasized that future obesity care should look beyond weight alone. Patient-reported outcomes like reduced food noise may prove just as meaningful as clinical measures.
Sources
